BioSpace News Archive

Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd announced publication of a cover article in the September issue of Nature Medicine featuring clinical data from the pivotal study “JUPITER-02”, a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.

Junshi Biosciences and Coherus Announce Results from Phase 3 Study of Toripalimab

The Rare Disease Cures Accelerator-Data and Analytics Platform initiative officially launched its next phase on Tuesday establishing itself as the leading platform to accelerate rare disease treatment innovation.

NextGen Healthcare to Participate at the Cantor Virtual Global Healthcare 2021 Conference

Tesis Labs announced it has been selected by Premier Health, an accountable care organization (ACO) serving communities in Georgia to provide clinicians and practices in detecting chronic and hereditary conditions in patients.

Simulations Plus Releases ADMET Predictor ® (X.3)

Echosens announces the release of its white paper, “Early Detection, Healthy Diet and Lifestyle Changes Critical for Addressing Metabolic Syndrome and Halting Progression of Liver Disease,” authored by Dr. Juan Pablo Frias, M.D., medical director and principal investigator, National Research Institute, Los Angeles.

Biosplice Therapeutics, Inc. (“Biosplice”), and Haisco Pharmaceutical Group Co., Ltd. (“Haisco”), a pharmaceutical company based in the People’s Republic of China (“China”), announced the execution of a licensing agreement that grants Haisco the right to develop and exclusively commercialize lorecivivint (SM04690) for the treatment of knee osteoarthritis (“OA”) and other musculoskeletal conditions in China.

Ampio Pharmaceuticals (NYSE American: AMPE), today announced top-line results from AP-013, a randomized, saline-controlled, double-blind Phase III clinical study evaluating the efficacy of an intra-articular (IA) injection of Ampion™ in adults with pain due to severe osteoarthritis of the knee (OAK).

Illumina, Inc. has selected seven new genomics companies to join the third global funding cycle of Illumina Accelerator.